Safety and Efficacy of Bromodomain and Extra-Terminal Inhibitors for the Treatment of Hematological Malignancies and Solid Tumors: A Systematic Study of Clinical Trials

Background: The upregulated expression of BET proteins is closely associated with the occurrence and development of hematological malignancies and solid tumors. Several BET inhibitors have been developed, and some have been in phase I/II of clinical trials. Here, the safety, efficacy, and pharmacody...

Descripción completa

Detalles Bibliográficos
Autores principales: Sun, Yanli, Han, Jie, Wang, Zhanzhao, Li, Xuening, Sun, Yanhua, Hu, Zhenbo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7870522/
https://www.ncbi.nlm.nih.gov/pubmed/33574760
http://dx.doi.org/10.3389/fphar.2020.621093

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7870522/
https://www.ncbi.nlm.nih.gov/pubmed/33574760
http://dx.doi.org/10.3389/fphar.2020.621093

Ejemplares similares